157. Sturge-Weber syndrome
[
6 clinical trials,
9 drugs（DrugBank:
4 drugs),
5 target genes / 55 target pathways ]
Searched query = "Sturge Weber syndrome", "Síndrome de Sturge Weber"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03047980 | January 2017 | 26 August 2019 | Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome | Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome | Sturge-Weber Syndrome | Drug: Sirolimus | Anne Comi, MD | Children's Hospital Medical Center, Cincinnati;Pfizer;National Institutes of Health (NIH);Faneca 66 Foundation;National Institute of Neurological Disorders and Stroke (NINDS) | Not recruiting | 3 Years | 31 Years | All | 10 | Phase 2/Phase 3 | United States |
| 2 | NCT02332655 | December 2014 | 21 January 2019 | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome | Sturge-Weber Syndrome | Drug: Cannabidiol | Anne Comi, MD | GW Pharmaceuticals Ltd.;Faneca 66 Foundation | Not recruiting | 1 Month | 45 Years | All | 10 | Phase 1/Phase 2 | United States |
| 3 | NCT01997255 | April 2014 | 17 May 2016 | Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) | An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome | Sturge Weber Syndrome | Drug: Everolimus | Baylor College of Medicine | Novartis Pharmaceuticals | Not recruiting | 2 Years | 18 Years | Both | 0 | Phase 2 | United States |
| 4 | NCT01533376 | February 2012 | 1 April 2019 | Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol | Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol | Sturge Weber Syndrome;Port-wine Mark | Drug: Timolol;Drug: Preservative free artificial tear gel. | Wills Eye | University of Medicine and Dentistry of New Jersey | Not recruiting | 2 Years | 10 Years | All | 3 | Phase 1 | United States |
| 5 | EUCTR2010-024078-20-ES | 11/05/2011 | 20 March 2012 | Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-Weber | Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-Weber | Malformación capilar cutánea en pacientes con síndrome de Sturge-Weber. MedDRA version: 13 Level: PT Classification code 10042265 Term: Síndrome de Sturge-Weber | Product Name: Rapamicina tópica al 1% y excipiente Pharmaceutical Form: Cream INN or Proposed INN: crema de rapamicina al 1% y excipientes Concentration unit: mg/g milligram(s)/gram Concentration type: equal Concentration number: 10- Product Name: Crema placebo (excipiente) Pharmaceutical Form: Cream INN or Proposed INN: Crema placebo (excipiente) Concentration type: up to Concentration number: 0- Pharmaceutical form of the placebo: Cream Route of administration of the placebo: Topical use (Noncurrent) | Instituto Científico y Tecnológico de Navarra | Not Recruiting | Female: yes Male: yes | Spain | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT00639730 | May 2006 | 19 February 2015 | Use of the Atkins Diet for Children With Sturge Weber Syndrome | Use of the Atkins Diet for Children With Sturge Weber Syndrome | Epilepsy;Sturge Weber Syndrome | Dietary Supplement: modified Atkins diet | Johns Hopkins University | Vascular Birthmarks Foundation | Not recruiting | 2 Years | 18 Years | Both | 5 | Phase 1 | United States |